Elsmarieke M Van De Giessen
Overview
Explore the profile of Elsmarieke M Van De Giessen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuhn E, Klinger H, Amariglio R, Wagner M, Jessen F, Duzel E, et al.
Alzheimers Dement
. 2025 Feb;
PMID: 39985404
Introduction: Specific features of subjective cognitive decline (SCD-plus) have been proposed to indicate an increased risk of preclinical Alzheimer's disease (AD). However, few studies have examined how these features relate...
2.
de Rijke T, Hendriksen H, Fruijtier A, Van Harten A, van Leeuwenstijn-Koopman M, Van De Giessen E, et al.
Patient Educ Couns
. 2025 Feb;
134:108668.
PMID: 39893987
Objectives: We disclosed amyloid PET results to people with subjective cognitive decline (SCD) and analysed audiotaped consultations. The aim was to examine the needs expressed by people with SCD and...
3.
Curro K, van Nispen R, den Braber A, Van De Giessen E, van de Kreeke J, Tan H, et al.
Invest Ophthalmol Vis Sci
. 2024 Oct;
65(12):2.
PMID: 39361291
Purpose: To investigate if changes in vessel density (VD) and the foveal avascular zone (FAZ) occur in the preclinical phase of Alzheimer's disease (pAD) over time. Methods: Optical coherence tomography...
4.
Verberk I, Jutte J, Kingma M, Vigneswaran S, Gouda M, van Engelen M, et al.
Alzheimers Dement
. 2024 Aug;
20(9):6115-6132.
PMID: 39096164
Introduction: We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P-)tau181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). Methods:...
5.
Padrela B, Mahroo A, Tee M, Sneve M, Moyaert P, Geier O, et al.
BMJ Open
. 2024 Mar;
14(3):e081635.
PMID: 38458785
Introduction: Loss of blood-brain barrier (BBB) integrity is hypothesised to be one of the earliest microvascular signs of Alzheimer's disease (AD). Existing BBB integrity imaging methods involve contrast agents or...
6.
Dubbelman M, Hendriksen H, Harrison J, Vijverberg E, Prins N, Kroeze L, et al.
Neurology
. 2024 Jan;
102(2):e207978.
PMID: 38165338
Background And Objectives: It is unclear to what extent cognitive outcome measures are sensitive to capture decline in Alzheimer disease (AD) prevention trials. We aimed to analyze the sensitivity to...
7.
Verveen A, Verfaillie S, Visser D, Csorba I, Coomans E, Koch D, et al.
BMJ Open
. 2023 Jul;
13(6):e072611.
PMID: 37399444
Introduction: The risk factors for persistent fatigue and cognitive complaints after infection with SARS-CoV-2 and the underlying pathophysiology are largely unknown. Both clinical factors and cognitive-behavioural factors have been suggested...
8.
Henssen D, Leijten L, Meijer F, van der Kolk A, Arens A, Laan M, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37174097
The post-treatment imaging surveillance of gliomas is challenged by distinguishing tumor progression (TP) from treatment-related abnormalities (TRA). Sophisticated imaging techniques, such as perfusion-weighted magnetic resonance imaging (MRI PWI) and positron-emission...
9.
van der Zwaal E, de Weijer B, Van De Giessen E, Janssen I, Berends F, van de Laar A, et al.
Eur Neuropsychopharmacol
. 2016 May;
26(7):1190-200.
PMID: 27184782
In several studies reduced striatal dopamine D2/3 receptor (D2/3R) availability was reported in obese subjects compared to lean controls. Whether this is a reversible phenomenon remained uncertain. We previously determined...
10.
Borgers A, Alkemade A, Van De Giessen E, Drent M, Booij J, Bisschop P, et al.
EJNMMI Res
. 2013 Apr;
3(1):34.
PMID: 23618227
Background: Serotonergic neurons in the rodent hypothalamus are implicated in key neuroendocrine and metabolic functions, including circadian rhythmicity. However, the assessment of the serotonergic system in the human hypothalamus in...